公开(公告)号：US20210292431A1

公开(公告)日：2021-09-23

申请号：US17343163

申请日：2021-06-09

Applicant: MORPHOSYS AG

Inventor： Michael TESAR ,  Ute JÄGER

IPC: C07K16/30 ,  C07K16/28 ,  C07K16/40

Abstract: The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.

公开(公告)号：US20150368323A1

公开(公告)日：2015-12-24

申请号：US14647459

申请日：2013-12-20

Applicant: MORPHOSYS AG

Inventor： Christoph Michael ERNST ,  Andreas Paul PESCHEL ,  Alexandra KRAUS ,  Michael TESAR

IPC: C07K16/12 ,  A61K38/12 ,  A61K39/40

CPC classification number: C07K16/1271 ,  A61K38/12 ,  A61K39/40 ,  A61K2039/505 ,  C07K2317/30 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/76

Abstract: This disclosure generally relates to antibodies or fragments thereof which interact with the bacterial protein MprF. The disclosure further discloses antibodies, which bind to specific extracellular motifs of MprF. The disclosure further relates to therapeutics comprising MprF-specific antibodies and methods of treatment using MprF-specific antibodies or fragments thereof.

Abstract translation: 本公开内容通常涉及与细菌蛋白MprF相互作用的抗体或其片段。 本公开进一步公开了结合MprF的特异性细胞外基序的抗体。 本公开还涉及包含MprF特异性抗体的治疗剂和使用MprF特异性抗体或其片段的治疗方法。

公开(公告)号：US20240309109A1

公开(公告)日：2024-09-19

申请号：US18418804

申请日：2024-01-22

Applicant: MORPHOSYS AG

Inventor： Michael TESAR ,  Ute JÄGER

IPC: C07K16/30 ,  C07K16/28 ,  C07K16/40

CPC classification number: C07K16/3061 ,  C07K16/2896 ,  C07K16/40 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/732

Abstract: The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.